Rigel Pharmaceuticals (NASDAQ: RIGL) on Tuesday, soared 6.93% from the previous trading day, before settling in for the closing price of $22.67. Within the past 52 weeks, RIGL’s price has moved between $8.61 and $29.82.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 279.46%. With a float of $17.37 million, this company’s outstanding shares have now reached $17.87 million.
Let’s look at the performance matrix of the company that is accounted for 164 employees. In terms of profitability, gross margin is 89.64%, operating margin of 21.63%, and the pretax margin is 18.77%.
Rigel Pharmaceuticals (RIGL) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Rigel Pharmaceuticals is 2.79%, while institutional ownership is 77.54%. The most recent insider transaction that took place on Feb 04 ’25, was worth 42,595. In this transaction EVP & Chief Financial Officer of this company sold 2,036 shares at a rate of $20.92, taking the stock ownership to the 58,969 shares. Before that another transaction happened on Feb 05 ’25, when Company’s EVP & Chief Financial Officer sold 1,734 for $21.93, making the entire transaction worth $38,020. This insider now owns 57,235 shares in total.
Rigel Pharmaceuticals (RIGL) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 279.46% per share during the next fiscal year.
Rigel Pharmaceuticals (NASDAQ: RIGL) Trading Performance Indicators
Rigel Pharmaceuticals (RIGL) is currently performing well based on its current performance indicators. A quick ratio of 2.13 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.13. Likewise, its price to free cash flow for the trailing twelve months is 12.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.07, a number that is poised to hit 0.24 in the next quarter and is forecasted to reach 1.61 in one year’s time.
Technical Analysis of Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals (NASDAQ: RIGL) saw its 5-day average volume 0.44 million, a positive change from its year-to-date volume of 0.23 million. As of the previous 9 days, the stock’s Stochastic %D was 91.86%.
During the past 100 days, Rigel Pharmaceuticals’s (RIGL) raw stochastic average was set at 88.10%, which indicates a significant decrease from 90.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.08 in the past 14 days, which was lower than the 1.10 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.92, while its 200-day Moving Average is $19.73.
